Geron Corp
- Last sale
- Nov 6, 2026 · +3.98%
- Market cap
- $636.38M
- 644.24M shares
- Filings
- 1,013
Q3 2026−60.2% FY23 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2024derivedN/M FY24 yoy
Q3 2026N/M FY25 yoy
Q3 2026−1.8% FY25 yoy
- $636.38M
- —
- —
- 2.8×
- —
- —
FY2025 figures · derived
Price
Nov 6, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2023 | 2023-12-31 | $237,000 | reported | |
| FY 2022 | 2022-12-31 | $596,000 | reported | |
| FY 2021 | 2021-12-31 | $1,393,000 | reported | |
| FY 2020 | 2020-12-31 | $253,000 | reported | |
| FY 2019 | 2019-12-31 | $460,000 | reported | |
| FY 2018 | 2018-12-31 | $1,066,000 | reported | |
| FY 2017 | 2017-12-31 | $1,065,000 | reported | |
| FY 2016 | 2016-12-31 | $6,162,000 | reported | |
| FY 2015 | 2015-12-31 | $36,371,000 | reported | |
| FY 2014 | 2014-12-31 | $1,153,000 | reported | |
| FY 2013 | 2013-12-31 | $1,283,000 | reported | |
| FY 2012 | 2012-12-31 | $2,709,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2015 | $0.00 | — | $0.00 | — | 158.92M sh | +0.8% | — |
| FY2014 | $0.00 | — | $0.00 | — | 157.70M sh | +0.5% | 0.0% |
| FY2013 | $0.00 | — | $0.00 | — | 156.90M sh | +20.2% | — |
Segments
Products
LineFY2025ShareChange
Revenues Before Adjustments$223.11M55%+149.5%
Product revenues, net$183.62M45%+140.0%
Royalties$258.00K0.1%−48.3%
Government Rebates-$2.60M—N/M
Sales Returns And Allowance-$3.85M—N/M
Distributor service fees-$7.51M—N/M
Chargebacks-$25.53M—N/M
Other-$39.49M—N/M
Total$406.99M
Pharmaceutical preparations
Geron Corp is the 172nd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ZVRAZevra Therapeutics, Inc.$106.5M350.9%78.2%$663.8MOLMAOlema Oncology, Inc.———$658.8MCLYMClimb Bio, Inc.———$638.2M
GERNGeron Corp (this company)———$636.4M
ACRSAclaris Therapeutics, Inc.$7.8M58.2%829.6%$635.2MQNRXQuoin Pharmaceuticals Ltd.———$628.9MANNXAnnexon, Inc.———$625.8MWVEWave Life Sciences, Inc.$42.7M60.5%478.3%$622.3MABUSArbutus Biopharma Corp$14.1M128.2%237.9%$617.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Geron Corp · CIK 886744 · Engraved from SEC EDGAR